US2006069129A1PendingUtilityA1

Chemokine receptor binding heterocyclic compounds

Assignee: BRIDGER GARY JPriority: Dec 17, 1999Filed: Nov 16, 2005Published: Mar 30, 2006

Est. expiryDec 17, 2019(expired)· nominal 20-yr term from priority

Inventors:Gary Bridger Eva Maria Boehringer Dominique Schols Renato Skerlj David Bogucki

A61P 9/10A61P 35/02A61P 31/18A61P 43/00A61P 35/00A61P 25/28A61P 19/02A61P 19/00A61P 11/06C07D 413/12A61K 31/52C07D 257/02A61K 31/4439A61K 31/496A61K 31/33C07D 417/12C07D 403/12C07D 401/12Y02A50/30

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

Claims

exact text as granted — not AI-modified

1 . A method to treat atherosclerosis comprising administering 1,1′-[1,4-phenylenebis(methylene)]-bis,1,4,8,11-tetra-azacyclotetradecane, or a salt form thereof, to a subject in need of such treatment a compound of the formula.  
   
   
       2 . The method of  claim 1 , wherein said subject is a human.  
   
   
       3 . The method of  claim 1 , wherein said subject is a mammal.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.